Shares have bucked weakness in the biotech sector and risen 60% year to date. Dry eye disease is a lucrative indication for reproxalap (albeit with generic competition) and differentiation is apparent

Aldeyra Therapeutics, Inc. (ALDX) Now Trades Above Golden Cross: Time to Buy?

01:55pm, Monday, 15'th Aug 2022 Zacks Investment Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Although US stocks closed mixed on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock

Aldeyra Therapeutics (ALDX) Q2 2022 Earnings Call Transcript

07:00am, Sunday, 07'th Aug 2022 The Motley Fool
ALDX earnings call for the period ending June 30, 2022.
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX ) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Bruce Greenberg - Interim Chief Financial Officer Todd Brady - President & Chi
Reproxalap seems poised for FDA approval for dry eye disease. Therapy has clear practical advantages over Restasis and Xiidra.
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Friday, August 5, 2022 to report financial results for the quarter en

Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals

02:53pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.
Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.

Boeing, PriceSmart And 80 Biggest Movers From Yesterday

08:59am, Wednesday, 13'th Jul 2022 Benzinga
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.
Aldeyra Therapeutics Inc (NASDAQ: ALDX) achieved the primary endpoints in a crossover clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate for dry eye disea
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, July 12, 2022, at 8:00 a.m. (ET) to report
Aldeyra Therapeutics Inc's (NASDAQ: ALDX) Phase 3 TRANQUILITY-2 trial of reproxalap for dry eye disease has achieved the primary endpoint. Reproxalap was statistically superior to the vehicle for ea
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Wednesday, June 8, 2022, at 8:00 a.m. (ET) to provi
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today ann
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE